This company has been marked as potentially delisted and may not be actively trading. NASDAQ:SNCE Science 37 (SNCE) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Science 37 Stock (NASDAQ:SNCE) Get Science 37 alerts:Sign Up Key Stats Today's Range$5.75▼$5.7550-Day Range$5.68▼$5.7552-Week Range$3.73▼$12.96VolumeN/AAverage Volume43,227 shsMarket Capitalization$34.33 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Science 37 Holdings, Inc. engages in patient-centric clinical trial activities in North Carolina. Its platform enables modern and digital approaches to clinical research, including the patient and trial investigators, nurses, coordinators, and sponsors, standardize evidence generation, and harmonize data. The company's platform also provides specialized networks of patient communities, telemedicine investigators, mobile nurses, remote coordinators, and connected devices for orchestrating clinical trials; and extensive configuration to support virtually any phase of clinical study and therapeutic area. In addition, the company licenses its proprietary hosted technology platform to various life science institutions. It serves large and mid-sized pharmaceutical companies, contract research organizations, academic institutions, and biotech companies. Science 37 Holdings, Inc. was founded in 2014 and is based in Research Triangle Park, North Carolina. As of March 11, 2024, Science 37 Holdings, Inc. operates as a subsidiary of eMed, LLC. Read More Receive SNCE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Science 37 and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SNCE Stock News HeadlinesScience 37 Completes Third FDA Inspection, Validating Quality of its Direct-to-Patient Site in Pivotal Phase 3 Rare Disease TrialOctober 8, 2025 | globenewswire.comScience 37 and Catalent Announce Partnership Enabling Universal Access to Clinical ResearchSeptember 4, 2025 | globenewswire.comOptions Pro Reveals His #1 Retirement Income TradeIf you want a way to generate consistent market income without chasing volatile AI stocks or complex crypto trades, you’ll want to see my new e-book, How To Master The Retirement Trade. It reveals a simple, time-based strategy that targets trades designed to play out in as little as 11 hours — no guesswork, no hype.October 14 at 2:00 AM | Base Camp Trading (Ad)Science 37 Holdings Inc (SNCE) - Investing.com UKJune 29, 2025 | uk.investing.comUS govt's science foundation purges 37 divisions, equity unit among casualtiesMay 9, 2025 | msn.comScientists Produced a Particle of Light That Simultaneously Accessed 37 Different DimensionsFebruary 3, 2025 | msn.comClinical researcher, cabinet maker cancel North Carolina jobs grants citing financial challenges, acquisitionsJanuary 14, 2025 | msn.comScience 37 Appoints Tyler Van Horn as CEO to Lead Next Era of Patient-Access InnovationJanuary 14, 2025 | tmcnet.comSee More Headlines SNCE Stock Analysis - Frequently Asked Questions When did Science 37's stock split? Science 37 shares reverse split before market open on Friday, December 8th 2023.The 1-20 reverse split was announced on Friday, December 8th 2023. The number of shares owned by shareholders was adjusted after the market closes on Friday, December 8th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. What other stocks do shareholders of Science 37 own? Based on aggregate information from My MarketBeat watchlists, some other companies that Science 37 investors own include Meta Platforms (META), NVIDIA (NVDA), Sangamo Therapeutics (SGMO), Broadcom (AVGO), Builders FirstSource (BLDR), Adobe (ADBE) and Advanced Micro Devices (AMD). Company Calendar Today10/14/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Health Information Services Sub-IndustryN/A Current SymbolNASDAQ:SNCE CIK1819113 Webwww.lifesciacquisition.com Phone984-377-3737FaxN/AEmployees460Year Founded2014Profitability EPS (Trailing Twelve Months)($21.40) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$50.99 million Net Margins-206.86% Pretax Margin-207.00% Return on Equity-83.09% Return on Assets-61.58% Debt Debt-to-Equity RatioN/A Current Ratio4.17 Quick Ratio4.17 Sales & Book Value Annual Sales$60.26 million Price / Sales0.57 Cash FlowN/A Price / Cash FlowN/A Book Value$16.70 per share Price / Book0.34Miscellaneous Outstanding Shares5,970,000Free Float5,564,000Market Cap$34.33 million OptionableNot Optionable Beta0.55 Social Links Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NASDAQ:SNCE) was last updated on 10/14/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | Sponsored$3,600 gold is nice ... but here’s what most gold bugs are missingGold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | SponsoredAltucher: It Looks Like My Trump prediction is coming trueNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredWhat Wall Street Won’t Say Out LoudDiscover the 7 key indicators before everyone else doesAmerican Alternative | SponsoredOptions Pro Reveals His #1 Retirement Income TradeIf you want a way to generate consistent market income without chasing volatile AI stocks or complex crypto tr...Base Camp Trading | SponsoredBuy this stock before Tesla’s November 6 announcementThe End of Tesla? "Hold onto your Tesla stock." That's the message insiders at Tesla have been giving staff...Altimetry | SponsoredNvidia’s slow death marchEric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Science 37 Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Science 37 With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
